Compare Norwegian Cruise Line Holdings Ltd (NCLH) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Norwegian Cruise Line Holdings Ltd vs Travere Therapeutics Inc. Common Stock — how do they compare? Norwegian Cruise Line Holdings Ltd trades at $14.96 (market cap $7.03B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Norwegian Cruise Line Holdings Ltd is the larger of the two by market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, Norwegian Cruise Line Holdings Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Norwegian Cruise Line Holdings Ltd for 69 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| NCLH | TVTX | |
|---|---|---|
Market Cap | $7.03B | $4.88B |
Volume | 12,698,429 | 1,668,577 |
Sector | Consumer Cyclical | Health |
52-Week High | $25.02 | $67.52 |
52-Week Low | $14.12 | $26.79 |
Typical Hold Time | 69 Days | 0 Days |
Enterprise Value | $21.85B | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NCLH trades at $15.32, down 0.2% on the day, with a neutral technical signal and bearish moving averages. The company reported Q2 2026 EPS of $0.48, beating expectations, and expects Q3 results to exceed guidance. Revenue grew to $9.83B in 2025, with a net income margin of 4.3%. Valuation ratios appear attractive with a P/E of 9.28 and P/S of 0.74. Recent news highlights pricing strategies to boost advance bookings and a $950M senior notes offering.
The outlook is mixed: strong earnings beats and analyst buy consensus (51.35%) support upside to the $20.86 price target, but high debt levels and yield pressure pose risks. Investors should weigh solid fundamentals against industry headwinds and financial leverage.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Norwegian Cruise Line Holdings Ltd
Norwegian Cruise Line is the world's third-largest cruise company by berths (at more than 62,000), operating 29 ships across three brands (Norwegian, Oceania, and Regent Seven Seas), offering both freestyle and luxury cruising. The company has redeployed its entire fleet as of May 2022. With eight passenger vessels on order among its brands through 2027 (representing 20,000 incremental berths), Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sailed to around 500 global destinations before the pandemic.
Read more on NCLH →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
